share_log

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K: Current report

Panbela Therapeutics | 8-K：重大事件
美股SEC公告 ·  03/26 16:16

Moomoo AI 已提取核心訊息

On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
On March 26, 2024, Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, issued a press release announcing its financial results for the year ended December 31, 2023. The announcement, filed with the SEC on Form 8-K, highlighted the company's business updates, including clinical trial progress and financial milestones. Panbela reported a net loss of $6.5 million, or $65.90 per diluted share, for the fourth quarter of 2023, compared to a net loss of $4.7 million, or $344.61 per diluted share, for the same period in 2022. Research and development expenses increased to $6.1 million from $3.5 million year-over-year. The company also completed a public offering on January 31, 2024, raising approximately $9 million. Panbela's pipeline includes clinical trials focusing on various cancers and diabetes, with its lead assets being Ivospemin (SBP-101) and Flynpovi. The company's ASPIRE trial for untreated metastatic pancreatic ductal adenocarcinoma has exceeded 50% enrollment, with full enrollment expected by Q1 2025. Panbela's stock is listed on The Nasdaq Stock Market LLC under the symbol 'PBLA'.
2024年3月26日，處於臨床階段的生物製藥公司Panbela Therapeutics, Inc. 發佈了一份新聞稿，公佈了截至2023年12月31日的年度財務業績。該公告通過8-K表格向美國證券交易委員會提交，重點介紹了該公司的業務更新，包括臨床試驗進展和財務里程碑。Panbela報告稱，2023年第四季度淨虧損650萬美元，攤薄每股虧損65.90美元，而2022年同期淨虧損470萬美元，攤薄每股虧損344.61美元。研發費用從同比的350萬美元增加到610萬美元。該公司還於2024年1月31日完成了公開募股，籌集了約900萬美元。Panbela的研發項目包括以各種癌症和糖尿病爲重點的臨床...展開全部
2024年3月26日，處於臨床階段的生物製藥公司Panbela Therapeutics, Inc. 發佈了一份新聞稿，公佈了截至2023年12月31日的年度財務業績。該公告通過8-K表格向美國證券交易委員會提交，重點介紹了該公司的業務更新，包括臨床試驗進展和財務里程碑。Panbela報告稱，2023年第四季度淨虧損650萬美元，攤薄每股虧損65.90美元，而2022年同期淨虧損470萬美元，攤薄每股虧損344.61美元。研發費用從同比的350萬美元增加到610萬美元。該公司還於2024年1月31日完成了公開募股，籌集了約900萬美元。Panbela的研發項目包括以各種癌症和糖尿病爲重點的臨床試驗，其主要資產是Ivospemin（SBP-101）和Flynpovi。該公司針對未經治療的轉移性胰腺導管腺癌的ASPIRE試驗的入組人數已超過50％，預計到2025年第一季度將全部入組。Panbela的股票在納斯達克股票市場有限責任公司上市，股票代碼爲 “PBLA”。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間